We investigated the association of urinary bladder cancer with genetic polymorphisms in the xeroderma pigmentosum complementation group C (XPC), group D (XPD) and group G (XPG), X-ray repair cross-complementing group 1 (XRCC1) and group 3 (XRCC3), Nijmegen breakage syndrome 1 (NBS1), cyclin D1, methylene-tetrahydrofolate reductase (MTHFR), NAD(P)H dehydrogenase quinone 1 (NQO1), H-ras and glutathione S-transferase theta 1 (GSTT1) genes. Bladder cancer patients from the different hospitals in Stockholm County Council area and matching controls were genotyped for different polymorphisms. The frequency of the variant allele for A/C polymorphism in exon 15 of the XPC gene was significantly higher in the bladder cancer cases than in the controls (OR 1.49, 95% CI 1.16EE1.92, P 0.001). The variant allele homozygote genotype for the T/C polymorphism in exon 1 of the H-ras gene was associated with a decreased risk for bladder cancer (OR 0.12, 95% CI 0.02EE0.67, P 0.006). The variant allele genotypes for the single nucleotide polymorphisms (SNPs) in DNA repair genes, XPG and NBS1, showed a marginal association with the occurrence of bladder cancer (OR 0.38, 95% CI 0.15EE0.94, P 0.03 and OR 1.64, 95% CI 0.92EE2.90, P 0.09, respectively). We also report a positive correlation between the null homozygote of GSTT1 with the risk of bladder cancer (OR 2.54, 95% CI 1.32EE4.98, P 0.003). For other polymorphisms included in this study, NBS1
Introduction
Urinary bladder cancer is the fourth most common neoplasm in men in the western world with urothelial cell carcinoma being the most common sub-type (1). The incidence in Sweden is about 32 for men and nine for women per 10 5 persons-years (approximately 1500 and 600 cases, respectively) (2). The established risk factors for bladder cancer include cigarette smoking, exposure to industrially related aromatic amines and uptake of drugs like phenacetine, chlornaphrazine and cyclophosphamide (3, 4) . The exposure to such environmental agents and by-products of cellular metabolism results in damage to DNA, which, if left un-repaired, can lead to the process of carcinogenesis. The entire process leading to DNA damage and subsequent repair of the damage involves a host of enzymes (5) . DNA damage itself is a consequence of a balance between activation and detoxification of carcinogens that involves phase I and II metabolic enzymes, many of which are polymorphic (6) . The genetic polymorphisms in a number of metabolic enzymes have been found as the modulators of bladder cancer risk (7, 8) .
The repair of damaged DNA is essential to protect cells against cancer (5) . Different pathways of DNA repair operate on specific types of damaged DNA, and each pathway involves numerous molecules (9) . Until now, enzymes coded by more than 100 genes have been found in human cells that are implicated in four major DNA repair pathways including nucleotide excision repair (NER), base excision repair (BER), double strand break repair and mismatch repair (10EE12). A deficiency in repair capacity due to the defect in genes involved in DNA repair can lead to genomic instability and carcinogenesis. Individuals with a repair capacity below the population mean can be at an increased risk of developing different kinds of cancer. DNA polymorphism can result in a subtle structural alteration of the repair enzymes and modulation of cancer susceptibility (13) .
A number of studies have investigated the probable association between modulation of bladder cancer risk and polymorphisms in metabolic, DNA repair and cell-cycle regulation genes (14EE20). The genes studied for association between polymorphism and bladder cancer risk include mainly xeroderma pigmentosum complementation group D (XPD), X-ray repair cross-complementing group 1 (XRCC1) and group 3 (XRCC3), cyclin D1 and methylene-tetrahydrofolate reductase (MTHFR) with not so clear and in some cases contradictory results. Besides, polymorphisms in the H-ras gene have also been associated with the risk of bladder cancer (19, 20) . Several meta-analyses with pooled data have shown that individuals with alleles associated with NAT2 slow acetylator phenotypes and individuals with glutathione S-transferase M1 null alleles are at an increased risk of bladder cancer (7, 8, 21) . These associations probably reflect the role of geneEE environment interactions in the etiology of bladder cancer. Several other studies have also indicated rather ambiguously the role of polymorphisms in other metabolic genes in bladder cancer, including glutathione S-transferase theta 1 (GSTT1) and NAD(P)H dehydrogenase quinone 1 (NQO1) (22, 23) .
In the present study we set to investigate the relation between genetic polymorphism and associated bladder cancer risk in patients recruited in hospitals from the Stockholm area. We examined the role of polymorphisms in genes involved in DNA repair, metabolism and cell-cycle regulation in a moderate sized single study population. We included polymorphisms with functional relevance in the relevant genes. The selected polymorphisms displayed high enough variant allele frequencies (usually over 20%) allowing us to detect a 2-fold increase or decrease in the relative risk. We studied the association of 12 single nucleotide polymorphisms (SNPs) and one homozygous deletion in 11 different genes with risk of bladder cancer. The SNPs studied included xeroderma pigmentosum complementation group C (XPC) exon 15 (Lys939Gln, A/C); XPD exon 23 (Lys751Gln, A/C); xeroderma pigmentosum complementation group G (XPG) (Asp1104His); XRCC1 exon 10 (Arg399Gln, G/A); XRCC3 exon 7 (Thr241Met, T/C); Nijmegen breakage syndrome 1 (NBS1) exon 5 (Glu185Gln, G/C); cyclin D1 exon 4 (Pro241Pro, G/A); MTHFR exon 4 (Ala222Val, C/T) and exon 7 (Glu429Ala, A/C); NQO1 exon 4 (Arg139Trp, C/T) and exon 6 (Pro187Ser, C/T) and H-ras exon 1 (His27His, T/C). We also examine the effect of GSTT1 null genotype on the risk of bladder cancer.
Materials and methods

Study subjects
Blood samples from urinary bladder cancer patients were collected in urology clinics of seven hospitals in the Stockholm county council area in years 1995EE1996 as part of a collaborative study. A total of 546 patients of Caucasian origin were recruited but blood samples could be collected from only 327 individuals. The mean age of patients in this study was 70 years (range 33EE96 years). The controls were chosen from the same geographical area, ethnic background and approximately from the similar age group (24). The DNA from blood samples collected from the cases and the controls was extracted as described (24) . Smoking data for the cancer cases and the controls was only partially available, which however, showed roughly an equal distribution (data not shown).
Genotyping by RFLP Genotyping for polymorphisms in XPC Lys939Gln, XPD Lys751Gln, XPG Asp1104His, XRCC1 Arg399Gln, XRCC3 Thr241Met, Cyclin D1 Pro241Pro, MTHFR Ala222Val and Glu429Ala, NQO1 Arg139Trp and Pro187Ser and H-ras His27His were detected using PCREERFLP technique. PCR products were generated by using 10 ng of genomic DNA in 10 ml volume reactions containing 20 mM TrisEEHCl, 50 mM KCl, 2.0 mM MgCl 2 , 0.11 mM each dNTP, 0.3 mM each primer (Table I) Lithuania) that recognized and cut either wild-type or variant sequences at 37 C for at least 3 h. The digested PCR products were resolved on a 10% polyacrylamide gel (Bio-Rad, Hercules, CA) and stained with ethidium bromide for visualization under UV light. The genotype results were regularly checked and confirmed by direct DNA sequencing of the amplified fragments (25) . Most of the assays were carried out including samples with known genotypes as controls. Genotypes for polymorphisms without previously known samples were identified by sequencing twice independently; such samples were subsequently used as controls.
Determination of NBS1 polymorphism by real-time PCR The polymorphism in NBS1 exon 5 (Glu185Gln, G/C) was analyzed using the ABI Prism 7700 sequence detection system (Applied Biosystems, Foster City, CA). PCR was carried out in the presence of two fluorescent labeled probes (Table I) 
GSTT1 genotyping
A duplex PCR assay with a GAPDH fragment as an internal control was used for determination of GSTT1 null allele homozygotes. The 10 ml volume reaction included 10 ng genomic DNA, 20 mM TrisEEHCl, 50 mM KCl, 2.0 mM MgCl 2 , 0.11 mM each dNTP, 0.3 mM each primer (GSTT1 and GAPDH, Table I ), 5% DMSO and 0.3 U Platinum Taq DNA polymerase (Invitrogen) in a total volume of 10 ml. Products from each PCR reaction were separated on 10% TBE gel (Bio-Rad, Herculus, CA) followed by ethidium bromide staining and visualization under UV light.
Statistical analysis
Differences in genotype distributions and allele frequencies in the bladder cancer cases and the controls were compared for statistical significance using the Chi 2 -test (Yates corrected). The statistical significance for deviations from HardyEEWeinberg Equilibrium (HWE) were determined using the Pearson Chi 2 -test. Odds ratios with 95% confidence intervals were calculated for the alleles and genotypes between the bladder cancer cases and the controls. Using our sample size, the study had a power of 90% to detect a 2.5-fold increase of the relative risk assuming a 10% prevalence of the rare allele in the control group. For the variant allele frequency 420%, this study had 490% power to detect a 2.0-fold increase of the relative risk. Bonferroni correction was taken into consideration because of the multiple comparisons carried out in this study. According to this correction P value 0.004 was considered statistically significant.
Results
We have determined the frequency of 12 SNPs and one deletion polymorphism in 11 different genes that included the XPC, XPD, XPG, XRCC1, XRCC3, NBS1, cyclin D1, MTHFR, NQO1, H-ras and GSTT1 genes in bladder cancer cases and matching controls in order to evaluate the modulation of risk of urinary bladder cancer. The genotype distribution for all the SNPs studied was in accordance with HWE, except for polymorphism in exon 1 of the H-ras gene, which showed a significant deviation from HWE in the bladder cancer cases.
The frequency of the variant C-allele, for XPC exon 15 was found to be significantly higher in the bladder cancer cases than in the control population (P 0.001) and the carriers of this allele had an increased risk of bladder cancer (OR 1.49, 95% CI 1.16EE1.92) (Table II) . Among the five other DNA repair genes studied, the genotype frequency for homozygote C/C in XPG exon 15 showed a significant difference between the cases and the controls (OR 0.38, 95% CI 0.15EE0.94, P 0.03). Similarly NBS1 exon 5 showed a marginally significant difference between the bladder cancer cases and the controls (OR 1.64, 95% CI 0.92EE2.90, P 0.09). However, when the Bonferroni correction for multiple comparisons was taken into consideration, the only statistical significance retained was for the differences in the allelic frequencies of XPC polymorphism between the cases and controls.
Among the metabolic genes, an association was found between the occurrence of urinary bladder cancer and the null allele homozygote of GSTT1 (OR 2.54, 95% CI, 1.32EE4.98, P 0.003). The distribution of the variant homozygote for T/C polymorphism in exon 1 of the H-ras gene was lower in the cases than in the controls, although the difference was not statistically significant after the correction for multiple comparisons. The variant allele seems to play a protective role against bladder cancer as its frequency in bladder cancer cases (25%) was lower than in controls (30%), although the difference in allele frequency was not statistically significant (Table II) .
For other SNPs in DNA repair genes (XPD Lys751Gln; XRCC1Arg399Gln; XRCC3 Thr241Met), cyclin D1G870A; MTHFR Ala222Val and Glu429Ala, NQO1 Arg139Trp and Pro187Ser, no statistically significant differences for genotype distributions or for allele frequencies between the patients and the controls were observed in the present study.
Discussion
DNA sequence variants are postulated to be responsible for the observed inter-individual differences in DNA repair and metabolic capacity; therefore, these variants probably modulate individual cancer risk (26, 27) . Our results from the present case-control study showed that amongst the DNA repair genes, the SNP in the XPC gene was strongly associated with an increased risk of bladder cancer. The frequency of the variant C-allele (instead of A-allele) that changes lysine to glutamine at codon 939 was higher in the bladder cancer cases than in the controls; the individuals homozygote for the variant allele were at an almost 2-fold increased risk of bladder cancer. XPC is an important component of NER and in complex with hHR23B, it is specifically involved in the recognition of the bases that cannot undergo the WatsonEECrick base pairing (28, 29) . To our knowledge, this is the first case-control study for this exonic polymorphism in XPC, although, in an earlier study an intronic insertion deletion poly AT polymorphism (PAT) in the gene has been shown to be associated with increased risk of squamous cell carcinoma of head and neck (30) . Interestingly, the variant C-allele at codon 939 has been reported to be in linkage disequilibrium with PAT allele in intron 9 and with variant A-allele of another polymorphism at splice site in intron 11 of the XPC gene (31) . In view of this haplotype linkage, our results assume importance, although it remains to be determined, which of these three variants in the gene modulates the cancer risk. The amino acid change causing SNP in the exon 15 is located in the C-terminus of XPC, which plays an important role in excision repair. On the other hand, a homozygous splice site variant in intron 11 of XPC causes increased skipping of exon 12. In vitro functional studies measuring DNA repair capacities have shown inconclusive and contradictory results (32, 33) .
No other polymorphisms in any of the DNA repair genes included in the present study showed a statistically significant difference between the bladder cancer cases and the healthy controls. The patients homozygote for variant alleles for Asp1104His XPG and Glu185Gln NBS1 polymorphisms showed statistically significant and marginally significant differences, respectively, when compared with the controls. Individuals with homozygote genotype for SNP at exon 15 of the XPG gene showed a decreased risk of bladder cancer. However, these differences after the Bonferroni correction for multiple comparisons did not retain the statistical significance. In an earlier study we reported a marginal association of the variant allele in the XPG gene with a risk of breast cancer (25) . Similar to earlier studies, we found no evidence of an association between polymorphisms in the XPD, XRCC1 and XRCC3 genes and bladder cancer risk (14EE16). Polymorphisms in metabolic enzymes that are involved with in vivo detoxification of carcinogens have been associated with risk of various cancers (6) . In particular, GST M1 and T1, involved in the detoxification of polycyclic aromatic hydrocarbon, and N-acetyl transferase-2, involved in acetylation of arylamines, are of interest in bladder cancer. Metaanalyses have shown that GSTM1 deficiency and slow acetylation are major determinants of bladder cancer susceptibility (7, 8) . Our results show that the deficiency of the GSTT1 also confers an increased risk of bladder cancer. The polymorphisms in the NQO1 gene did not show any association in this study.
Interestingly, our results show that homozygote carriers of the variant C-allele at the site of C/T polymorphism at codon 27 of the H-ras gene have a decreased risk of bladder cancer, but not statistically significant after Bonferroni correction. An earlier report found an opposite effect of this polymorphism on bladder cancer risk, taken together with the fact that this is a silent polymorphism; it is doubtful whether this SNP has any effect on the risk of bladder cancer (19) . Other non-coding variants of H-ras have been associated with the risk of many cancers; the rare alleles of H-ras variable tandem repeats have been also associated with bladder cancer risk (20) . The variable tandem repeat located downstream of exon 4 of the H-ras gene can possibly have an effect on the transcriptional activity (34) . The polymorphism in the other two genes included in the study, cyclin D1 and MTHFR, did not show any difference in the frequency between the cases and the controls. The polymorphism at the splice site in exon 4 of the cyclin D1 gene, which results in increased alternate splicing, has been associated with an increased risk of bladder cancer in one study while another study did not show such an association (17, 18, 35) .
In conclusion, the results of this study based on the study of 13 polymorphisms in 11 genes show that the variant allele in exon 15 of the XPC gene is associated with an increased risk of bladder cancer, although the functional explanation for such an association remains undetermined. In addition, we report an association of increased bladder cancer risk with the GSTT1 null genotype.
